<DOC>
	<DOCNO>NCT02134067</DOCNO>
	<brief_summary>The purpose study determine safety TAS-119 determine appropriate dose combination Paclitaxel subsequent study patient advance solid tumor . TAS-119 novel , selective Aurora A kinase inhibitor , previously demonstrate enhance activity paclitaxel preclinical study</brief_summary>
	<brief_title>Dose-escalating , Safety , Tolerability PK Study TAS-119 Combination With Paclitaxel Patients With Advanced Solid Tumors</brief_title>
	<detailed_description>Background rationale study : In nonclinical pharmacology study TAS-119 significantly enhance antitumor activity microtubule stabilizer paclitaxel TAS-119 developed use combination paclitaxel . TAS-119 selectively inhibit kinase inhibitor Aurora A. AurA regulate cell division control transition G2 M phase . Overexpression AurA associate resistance taxanes . The study conduct two sequential phase : Dose Escalation Phase purpose determine maximum tolerate dose recommended Phase 2 dose TAS-119 give combination paclitaxel An Expansion Phase additional patient enrol evaluate safety preliminary efficacy recommend Phase 2 dose TAS-119 combination paclitaxel , subgroup patient evaluate DDI paclitaxel TAS-119 via PK assessment .</detailed_description>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>1 . Is male female ≥ 18 year age , provide write informed consent . 2 . Has histologically cytologically confirm advanced , unresectable metastatic solid tumor ( ) patient available therapy likely provide clinical benefit , paclitaxel consider standard care . 3 . Has adequate organ function define follow criterion : Aspartate aminotransferase ( AST/SGOT ) alanine aminotransferase ( ALT/SGPT ) ≤ 3.0 × upper limit normal ( ULN ) ; liver function abnormality due underlie liver metastasis , AST ( SGOT ) ALT ( SGPT ) ≤ 5 × ULN . Total serum bilirubin ≤ 1.5 × ULN . Absolute neutrophil count ≥ 1,500/mm3 ( exclude measurement obtain within 7 day administration granulocyte colonystimulating factor [ GCSF ] ) . Platelet count ≥ 100,000/mm3 ( IU : ≥ 100 × 109/L ) ( exclude measurement obtain within 7 day transfusion platelet ) . Hemoglobin ≥ 9.0 g/dL Total serum creatinine ≤ 1.5 × ULN Serum albumin ≥ 3.0 mg/dL . 1 . Previous inability tolerate dose paclitaxel ( i.e. , subject require paclitaxel dose reduction discontinuation ) . 2 . Has receive treatment prohibit trial within specified time frame 3 . Has serious illness medical condition ( ) would affect safety tolerability study treatment 4 . Has history Grade 2 great peripheral neuropathy 3 month prior enrollment . 5 . Has know hypersensitivity TAS119 component . 6 . Has know hypersensitivity Cremophor® EL , paclitaxel component . 7 . Is pregnant lactate female .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>advanced solid tumor</keyword>
	<keyword>tumor</keyword>
	<keyword>Dose Escalation</keyword>
	<keyword>TAS-119</keyword>
	<keyword>Taxane</keyword>
	<keyword>Paclitaxel</keyword>
	<keyword>Aurora A kinase inhibitor</keyword>
	<keyword>AurA</keyword>
</DOC>